The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: M&C Saatchi pulls Next Fifteen deal support

Fri, 17th Jun 2022 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Directa Plus PLC, up 10% at 107.00 pence, 12-month range 95.1p-178p. Sees an acceleration in trading in the last two months since the first quarter of the year. The graphene-based product supplier says that revenue from the start of the year to the end of May was approximately 44% ahead of the same period the previous year at EUR4.6 million. Directa Plus says this was driven by growth in all its commercial verticals, with sales in line with expectations.

----------

Bidstack Group PLC, up 6.4% at 2.40p, 12-month range 1.6p-6.15p. The in-game advertising platform hires David Reeves as chair designate to succeed Donald Stewart on September 1. The company says Reeves will serve as a non-executive director in the meantime. Stewart will move to a non-executive role and serve on the audit and remuneration Committees on Reeves' becoming the chair. Reeves has over 30 years' global experience in senior management roles within multinational companies across the video games industry, having working at Sony and Capcom.

----------

AIM - LOSERS

----------

ValiRx PLC, down 12% at 19.15p, 12-month range 17.3p-63p. The drug development company anticipates extension request to the exclusivity period between itself and TheroemRx Inc regarding the proposed sub-licence for VAL201. An exclusivity period was granted to June 30 to enable TheoremRx to progress its financing round, which the sub-licence of VAL201 depends. Progress on financing remains positive, but ValiRx anticipates that an extension to the exclusivity period will be requested and intends to seek "more formal confirmation" of the progress. "The letter of intent and proposed sub-license therefore remain non-binding and there is no guarantee that this sub-license will be executed or that it will generate material revenues within the expected timeframe or at all," it says.

----------

M&C Saatchi PLC, down 7.3% at 164p, 12-month range 122p-227p. Directors pull support for takeover offer by Next Fifteen Communications Group PLC, while still not supporting a rival offer by AdvancedAdvT Ltd. M&C Saatchi directors "no longer consider the terms of the Next 15 offer to be fair and reasonable solely on the basis of the deterioration in value of Next 15 shares since the announcement date," the London-based advertising agency explains. Since announcing its share-based acquisition offer in May, Next Fifteen shares have fallen by around 30%. M&C Saatchi, however, also warns that it may be prevented from delivering on its own plans as a standalone company. Shares in Next Fifteen fall 1.9% on Friday.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Jun 2019 09:54

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

Read more
13 Jun 2019 11:07

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

Read more
10 Jun 2019 09:50

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

Read more
5 Jun 2019 10:54

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

Read more
31 May 2019 12:04

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

Read more
29 May 2019 10:41

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

Read more
29 May 2019 10:19

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

Read more
2 May 2019 15:21

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

Read more
2 May 2019 09:51

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

Read more
26 Apr 2019 14:54

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

Read more
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.